What Shingrix Treats: Main Uses and Benefits

Quick Facts: Primary Therapeutic Domain
Therapeutic Purpose: May assist in reducing the likelihood of developing shingles (herpes zoster).
Primary Patient Groups: Adults aged 50 years and older.
Additional Patient Groups: Adults aged 18 years and older who are, or will be, at increased potential risk of shingles due to known disease or therapy.
Additional Benefit: May also help reduce the risk of experiencing postherpetic neuralgia (PHN), which is a common potential complication of shingles.

---

Shingrix is a medical intervention utilized in the preventative care of shingles, a condition caused by the reactivation of the varicella zoster virus. It is intended for administration in adults aged 50 and older to help bolster the body's natural defenses against the virus.

This recombinant vaccine is also indicated for use in adults aged 18 years and older who have a heightened potential for developing shingles due to factors such as being immunocompromised or undergoing specific therapies. By supporting protection against the herpes zoster infection, use of Shingrix may assist in reducing the risk of developing subsequent postherpetic neuralgia (PHN), a long-term nerve pain that can follow an episode of shingles.

This medication is specifically for the prevention of herpes zoster; it is not indicated for the prevention of the primary varicella infection (chickenpox).

Regulatory References

1. FDA package insert guidance

Eligibility Map: Who can and cannot use Shingrix — Official Regulatory Information

Eligibility Scope	Official Regulatory Statement
Populations Allowed	The vaccine is indicated for adults aged 50 years and older. It is also indicated for adults aged 18 years and older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy.
Absolute Contraindication	Use is contraindicated in any individual with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or following a previous dose of Shingrix.
Age-Related Restrictions	Safety and efficacy have not been established in the pediatric population (children and adolescents under 18 years), and use is officially not indicated for this specific age group.
Conditional Restrictions	Administration should be temporarily postponed in subjects suffering from an acute severe febrile illness. Caution is also advised for individuals with coagulation disorders or thrombocytopenia due to the risk of bleeding from the required intramuscular injection.
Pregnancy and Lactation	Data are insufficient to establish a vaccine-associated risk in pregnant women, and use is generally avoided as a precaution. The use of the vaccine during breastfeeding is not considered a contraindication if it is otherwise indicated.

---

Resulting Eligibility Structure

Official regulatory documents establish who can and cannot use the medicine through defined criteria. This profile begins with age-based inclusion and risk-based inclusion for adults. The only absolute exclusion is a history of severe hypersensitivity. Other limitations involve conditional postponement during acute illness or classifying use as not established for populations lacking sufficient regulatory data, such as children.

Interactions with other medicines and products

The official interaction profile for Shingrix is primarily defined by rules governing co-administration with other vaccines and the effects of immune-modifying therapies, rather than common drug-metabolism interactions.

Pharmacodynamic and Timing Interactions

Co-administration with immunosuppressive therapies may lead to a reduction in the intended immune response to Shingrix, an interaction classified as pharmacodynamic antagonism. This includes agents such as high-dose corticosteroids, chemotherapy, and biologics. For this reason, regulatory guidance recommends that administration be completed prior to the initiation of severe immunosuppression when clinically feasible.

Shingrix is officially permitted for concomitant administration (at separate injection sites) with several specific vaccines, including the inactivated seasonal influenza vaccine, the 23-valent pneumococcal polysaccharide vaccine (PPV23), and the reduced antigen diphtheria-tetanus-acellular pertussis (dTpa) vaccine. However, concomitant use with PPV23 has been documented to result in a greater frequency of reported fever and shivering compared to administration of Shingrix alone. Co-administration with any vaccine not specifically listed as tested is not recommended due to a lack of data.

Lack of Established Interactions

Regulatory documents confirm there are no established interactions with drug metabolic pathways such as the CYP450 enzyme system, drug transporters, food, alcohol, or herbal products.

Shingrix operates through a coordinated immunological mechanism involving a specific antigen and a proprietary adjuvant system. The vaccine contains the Varicella Zoster Virus (VZV) glycoprotein E (gE) antigen, which acts as the target recognition molecule. This recombinant protein is presented by antigen-presenting cells (APCs) to T-cells and B-cells, initiating the specific adaptive immune response.

---

Activation is facilitated by the AS01B adjuvant system, which contains the immunostimulants MPL and QS-21. These components modulate specific molecular signaling pathways within the APCs, leading to a local, transient activation of the innate immune system. This innate activation facilitates the subsequent recruitment and differentiation of T-cells and B-cells in the lymph nodes.

---

The integrated mechanism drives the differentiation and proliferation of gE-specific CD4+ T-cells and plasma cells. This results in the development of both humoral immunity (antibodies) and cellular immunity (T-cells), establishing an antigen-specific immunological state.

Shingrix is administered as an intramuscular injection only, delivered into the deltoid muscle of the upper arm. The full vaccination course consists of a total of two doses, with each dose volume standardized at 0.5 mL. This fixed-volume regimen defines the primary usage pattern for the vaccine.

Dosing Schedule and Administration

The standard schedule requires the second 0.5 mL dose to be administered 2 to 6 months after the initial dose. This interval applies to adults aged 50 years and older. For individuals aged 18 years and older who are, or will be, immunocompromised, the official instructions allow for an accelerated schedule. In this specific usage context, the second dose may be given 1 to 2 months following the first dose. If the second dose is missed or delayed beyond the recommended window, the entire series should not be restarted; the second dose should be given as soon as feasible to complete the course.

Preparation Protocol

The use protocol specifies that certain presentations of the vaccine require reconstitution, where the antigen component is mixed with the adjuvant component immediately prior to administration. Once reconstituted, the product must be used promptly or stored refrigerated and administered within 6 hours, after which it must be discarded. The need for subsequent booster doses following the two-dose primary series has not been established.

Evidence for Use in Adults Aged 50 Years and Older

The primary evidence base relies on large, placebo-controlled, observer-blind Phase III Randomized Controlled Trials (RCTs) (ZOE-50 and ZOE-70). The research examined outcomes related to the occurrence of shingles (Herpes Zoster, HZ) and associated Post-Herpetic Neuralgia (PHN) in generally healthy adults aged 50 and older. Findings described patterns in HZ occurrence and corresponding patterns in PHN development over an intermediate follow-up period of several years. Research also explored immunological measurements to understand how the body's immune response evolved.

---

Evidence for Use in Immunocompromised Adults

A separate body of evidence exists for adults aged 18 and older with specific underlying conditions or compromised immune systems who are at an increased potential risk of shingles. Initial pivotal trials focused on healthy individuals, leading to dedicated Phase III/IV clinical trials and post-market Real-World Effectiveness (RWE) studies for high-risk cohorts. The research examined outcomes related to HZ occurrence and measured T-cell and antibody response patterns in these distinct patient groups.

---

Long-Term Follow-up and Research Gaps

To explore the persistence of the patterns, research included Long-Term Open-Label Extension Studies that provided observational data extending beyond the initial RCTs. The evidence from these extended follow-up settings contributes to understanding long-term patterns; however, the certainty remains low because the assessments relied on comparisons with historical control data. Key uncertainties include limited data regarding the effect on PHN occurrence in subjects who had already developed confirmed HZ, as the studies were designed for prevention. Data for certain high-risk groups also remain insufficient due to smaller sample sizes, and research is ongoing to explore broader patterns related to cardiovascular and cognitive outcomes.

Key Studies & References

1. Label: SHINGRIX - zoster vaccine recombinant, adjuvanted kit (US Prescribing Information)

Common questions about Shingrix (FAQ)

Q: Can people who already had shingles get Shingrix?

Official recommendations state that eligible adults, including those aged 50 and older, are advised to receive the vaccine regardless of whether they have a history of having had shingles (Herpes Zoster). If a person is experiencing an acute shingles episode, the vaccination is postponed until the lesions have crusted and symptoms have abated.

Q: How long after getting the first shot can I wait for the second shot of Shingrix?

According to official prescribing information, the recommended interval for the second dose is typically 2 to 6 months after the first dose. If the time frame for the second dose has been missed or delayed, the entire vaccine series should not be restarted. Instead, the second dose should be administered as soon as feasible to adhere to the two-dose series as defined in clinical studies.

Q: Is it true that the side effects from Shingrix can be strong?

Regulatory safety data classifies the majority of reported side effects as transient and mild to moderate in intensity. However, clinical trials reported that approximately 1 in 10 generally healthy adults experienced Grade 3 systemic reactions. These reactions are officially defined as being severe enough to prevent normal daily activities.

Q: What are the most common injection site side effects reported for Shingrix?

The most frequently reported local adverse reaction at the injection site is pain, followed by redness and swelling.

Q: What are some common overall body side effects (systemic) reported with Shingrix?

Common overall body side effects (referred to as systemic reactions in official documents) reported are fatigue (feeling tired), myalgia (muscle aches), and headache. Other frequently reported systemic reactions include shivering, fever, and gastrointestinal symptoms.

Q: Is it normal to have a very sore or swollen arm after the Shingrix shot?

Injection site reactions such as pain and swelling are documented as Very Common, meaning they occur in 1 in 10 or more people. Clinical trial data reported that a small percentage of adults experienced severe (Grade 3) injection-site symptoms, which were defined as symptoms severe enough to prevent normal daily activities.

Q: Are there reports of fever or chills commonly occurring after Shingrix?

Fever and shivering (or chills) are documented as Common systemic reactions in the official safety profile. Clinical trial data reported that fever was experienced by approximately 7% of generally healthy adults aged 50 and older.

Q: Why do some people experience more intense side effects with the second dose of Shingrix?

Official documents show that for generally healthy adults aged 50–69, the occurrence of severe (Grade 3) systemic reactions was reported to be more frequent after the first dose than after the second dose. Incidence rates for most reactions were generally higher in the 50–69 age group compared to the 70 and above age group.

Q: Is the second dose still considered effective if the interval is longer than 6 months?

The effectiveness of the vaccine was demonstrated in studies where the two doses were given within the 2 to 6 month window. Official guidance for a delayed interval is not to restart the series but to administer the second dose as soon as feasible. Completion of the course is emphasized by official guidance to support the pattern of protection documented in clinical studies.

Q: What is the difference between Shingrix and the older shingles vaccine?

Shingrix is officially classified as a recombinant subunit vaccine that is inactivated (non-live). This differs from the older shingles vaccine (Zostavax), which was a live, attenuated vaccine.

Q: Is Shingrix intended to treat shingles after the rash has started?

No. Official documents classify Shingrix as a prophylactic agent, meaning its sole indication is for the prevention of shingles (Herpes Zoster) and its complication, Post-Herpetic Neuralgia (PHN). It is not indicated for the treatment of an active shingles infection.

Q: Why does the second dose of Shingrix need to be given within a certain time frame?

The schedule requiring the second dose within a certain time frame (2 to 6 months) is the specific regimen that was tested in the key clinical trials. This schedule was shown in clinical trials to produce the robust and sustained immune response pattern that led to the vaccine’s approval.

Q: Can the Shingrix shot cause shingles?

No. Shingrix is an inactivated (non-live) vaccine. It contains only a protein component (glycoprotein E) of the virus and not the whole, live virus. Therefore, regulatory documents confirm it is unable to cause shingles or chickenpox.

Q: Are there any specific chronic conditions that prevent people from getting Shingrix?

The only absolute contraindication listed in official regulatory documents is a history of a severe allergic reaction to any component of the vaccine. Chronic conditions such as diabetes or heart disease are not absolute contraindications. The vaccine is in fact indicated for adults aged 18 and older who are at increased risk of shingles due to underlying disease or therapy.

Q: Is it necessary to get Shingrix if a person does not remember having chickenpox?

Yes. Official recommendations advise vaccination for eligible adults regardless of whether they recall having had chickenpox. This is because more than 99% of adults aged 50 and older worldwide have been exposed to the virus that causes shingles, which stays dormant in the body.

Q: Can Shingrix be given at the same time as the flu shot?

Yes. Regulatory documents officially permit the concomitant administration of Shingrix with the inactivated seasonal influenza vaccine (flu shot). If given at the same time, the injections must be administered at separate injection sites.

Q: Can Shingrix be given if someone is currently taking antiviral medication?

Yes. Studies indicate that antiviral drugs active against herpesviruses, such as valacyclovir, are not known to interfere with the immune response to Shingrix, which is a non-live vaccine.

Q: Does Shingrix interact with common blood thinners like warfarin?

Official regulatory documents confirm there are no established interactions with drug metabolic pathways that would affect common blood thinners. However, caution is advised for individuals with coagulation disorders (blood clotting issues) due to the risk of bleeding from the required intramuscular injection.

Q: Is Shingrix considered safe for people with diabetes?

Diabetes is not listed as a contraindication. The vaccine is indicated for adults at increased risk of shingles due to underlying health conditions, and clinical trial safety data included subjects with diabetes mellitus.

Q: Can a person get the Shingrix series if they are pregnant or breastfeeding?

For pregnant women, data are insufficient to establish a vaccine-associated risk, and vaccination is generally deferred as a precaution. However, for breastfeeding, the use of the vaccine is not considered a contraindication if it is otherwise indicated, as non-live recombinant vaccines are not known to pose a risk to the infant.

Q: Is there official information about Shingrix being used in people with autoimmune diseases?

Yes. The vaccine is indicated for adults aged 18 and older who are at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy. Many people with autoimmune diseases fall into this expanded eligibility category, and research studies have examined the vaccine in these cohorts.

Q: Are there any ingredients in Shingrix that people with common food allergies should be aware of?

The vaccine is strictly contraindicated only if there is a known severe allergy to any of its components. Official ingredient lists do not typically include common food allergens like egg protein or gelatin.

Q: How does Shingrix compare to other vaccines in terms of reported side effects?

Clinical data reported that the overall incidence of transient local and systemic reactions (such as pain, fatigue, and fever) is generally higher compared to the older shingles vaccine (Zostavax).

Q: Do official sources provide a summary of the risks versus potential benefits of Shingrix?

Yes. Official documents describe the potential benefits as high, sustained protection against shingles and Post-Herpetic Neuralgia (PHN). Risks are summarized by the known side effect profile, which includes transient local and systemic reactions, and the documented occurrence of very rare serious adverse events reported in post-marketing experience.

Q: Can Shingrix be administered if someone has a minor cold or fever?

Official guidance states that administration should be temporarily postponed only in subjects suffering from an acute severe febrile illness. However, generally, having a minor cold or mild symptoms, such as a low-grade fever, is not considered a reason to delay the vaccine.

How to Store and Dispose of Shingrix?

The storage and disposal instructions for Shingrix are mandated by regulatory agencies to ensure product integrity.

Requirement	Official Regulatory Details
Storage Temperature	Both components must be stored refrigerated between 2 C and 8 C (36 F and 46 F).
Handling / Freezing	Do not freeze the vaccine at any time. The product must be discarded if it has been frozen.
Protection	Store in the original container to protect from light.
Stability (Post-Mixing)	After reconstitution, the vaccine must be administered immediately or used within 6 hours if kept refrigerated (2 C to 8 C).
Child Safety	Keep this medicine out of the sight and reach of children.
Disposal	Unused or expired product must be disposed of in accordance with local procedures; it must not be thrown away via household waste or wastewater.